Syndax Pharmaceuticals SNDX Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $134.93M-12.4% | $154.08M-47.8% | $295.39M+297% | $74.36M-66.5% | ||
| $259.14M-38.1% | $418.8M+52.1% | $275.3M-31.4% | $401.45M+84.2% | ||
| $98.58M+1,197% | $7.6M— | $0— | $0— | ||
| $80.11M+21,789% | $366K— | $0— | $0— | ||
| $528.08M-12.4% | $603.06M+3.8% | $580.88M+18.6% | $489.79M+9.2% | ||
| $181K— | $0-100% | $8K-60.0% | $20K-92.8% | ||
| $529.71M-26.9% | $724.82M+18.3% | $612.88M+23.3% | $497.24M+10.6% | ||
| $16.58M+42.6% | $11.63M+16.7% | $9.96M+129% | $4.35M-23.3% | ||
| $350M+3.6% | $337.88M— | $0— | —— | ||
| $120.12M+16.0% | $103.55M+78.2% | $58.1M+99.9% | $29.07M+40.5% | ||
| $344.96M+3.5% | $333.14M+56,557% | $588K-18.6% | $722K-96.5% | ||
| $465.08M+6.5% | $436.69M+644% | $58.68M+97.0% | $29.79M-27.9% | ||
| $9K0.0% | $9K+12.5% | $8K+14.3% | $7K+16.7% | ||
| -$1.51B-23.4% | -$1.22B-35.3% | -$902.4M-30.2% | -$693.04M-27.5% | ||
| $64.63M-77.6% | $288.12M-48.0% | $554.2M+18.6% | $467.45M+14.5% | ||
| $529.71M-26.9% | $724.82M+18.3% | $612.88M+23.3% | $497.24M+10.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Syndax Pharmaceuticals's total assets?
- Syndax Pharmaceuticals (SNDX) holds $472.7M in total assets, down 26.2% year over year.
- How much debt does Syndax Pharmaceuticals have?
- Syndax Pharmaceuticals carries $350.5M in total debt against $41.6M of shareholders' equity, a debt-to-equity ratio of 8.42.
- How much cash does Syndax Pharmaceuticals have?
- Syndax Pharmaceuticals holds $130.9M in cash and equivalents.
- Can Syndax Pharmaceuticals cover its short-term obligations?
- Its current ratio is 5.47 — current assets exceed current liabilities.
- Where does Syndax Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
